Table 2 Anticoagulation control, primary and secondary outcomes of included studies in the systematic review
Author ID | Primary outcomes | Secondary Outcomes | |||||
|---|---|---|---|---|---|---|---|
Method to determine TTR | Percentage of TTR | % of patients within the therapeutic range | % of patients with TTR ≥ 65% or indicated by a study | Bleeding during warfarin therapy (%) | Major bleeding (%) | Thromboembolic events (%) | |
Salaheldin A, 2019 [32] | Rosendaal and Direct Method | Median 37% by Rosendaal method, and median TTR 42.9% by Direct Method | NA | 23% of patients with TTR > 72% | 9.50 | NA | NA |
Karuri et al., 2019 [36] | Rosendaal method | Mean 31.1% (± 26.7) | 82% of MVR (mech); 54% of patients with MVR (prosthetic) | 10.4% of pts (TTR ≥ 70%) | NA | NA | NA |
Sana et al., 2020 [43] | Rosendaal method | Mean 48.87 ± 28.69% in 341 patients | NA | 32.50 | 5.80 | 5.80 | 1.64 |
Lauren et al., 2019Â [35] | Rosendaal and Direct Method | Mean 29.4% by Rosendaal method and 25.2% by direct method | NA | 10 | NA | NA | NA |
Sonuga et al., 2016 [37] | Cross-section-of-the-files method | 48.50% | 48 | NA | 14.00 | NA | 2.20 |
Fenta et al., 2017 [23] | Direct Method | Mean 29% | NA | NA | NA | NA | NA |
Semakula et al., 2020 [5] | Rosendaal method | Median 41% | NA | NA | NA | NA | NA |
Prinsloo et al., 2021 [38] | Rosendaal method | Median 37.2% | NA | 17.80% | NA | NA | NA |
Ahmed et al., 2017 [41] | Direct Method | BI mean 51.5% and AI 68.3% | BI mean 51.5% and AI 68.3% | NA | BI 37% of patients, AI 53 of patients | 0.00 | NA |
Botsile et al., 2020 [39] | Rosendaal method | Median 29.8% | NA | 14.80 | 14.10 | 14.10 | 22.50 |
Masresha et al., 2021 [31] | Rosendaal method | Mean 41% | NA | 29.20 | 4.50 | NA | 7.40 |
Kizito et al., 2016Â [47] | Cross-section-of-the-files method | Mean 43.5% | 43.50 | NA | NA | NA | NA |
Yimer et al., 2021[40] | Rosendaal method | Mean 42.03% | NA | 12.67 | 20.67 | NA | NA |
Sadhabiriss and Brown, 2021 [33] | Rosendaal method | Mean TTR for the AF group was 44.5% and for PHV was 13.7% | NA | 10.4% for the AF group had a range of more than 70% but none in the PHV group achieved this | 24.00 | NA | NA |
Ntlokotsi et al., 2018 [28] | Direct method | 49.70% | NA | Cut-off TTR was ≥ 70% | 0.006% per patient-year | NA | 0.002% per patient-year |
Rejeb et al., 2019 [29] | Rosendaal method | Mean 57.3% | NA | 24.5%; Cut-off TTR was ≥ 70% | 0.59 | 9.50 | 15 patients |
Mwita et al.,2017 [30] | Rosendaal method | Median 30.8% | NA | 14.90 | NA | NA | NA |
Ebrahim et al., 2018 [7] | Rosendaal method | Mean 47% | NA | 25.10 | NA | NA | NA |